Skip to main content

Table 1 Baseline characteristics by eosinophil stability

From: Serial blood eosinophils and clinical outcome in patients with chronic obstructive pulmonary disease

 

Persistently < 300

Variable

Persistently ≥300

P-value

Number

175

68

56

 

Age, years

67.1 (7.6)

66.0 (6.8)

66.6 (7.3)

0.59

Sex

   

0.18

 Female

3 (1.7)

4 (5.9)

1 (1.8)

 

 Male

172 (98.3)

64 (94.1)

55 (98.2)

 

Smoking history

   

0.28

 Current

52 (29.7)

23 (33.8)

23 (41.1)

 

 Ex-smoker

123 (70.3)

45 (66.2)

33 (58.9)

 

BMI, kg/m2

22.8 (3.5)

23.5 (2.7)

23.9 (3.0)

0.07

Education

   

0.63

  < high school

86 (49.1)

30 (44.1)

24 (42.9)

 

  ≥ high school

89 (50.9)

38 (55.9)

32 (57.1)

 

mMRC ≥2

98 (56.0)

31 (45.6)

28 (50.0)

0.32

SGRQ

 Symptoms

44.1 (19.0)

41.1 (18.8)

46.3 (16.9)

0.39

 Activity

48.6 (22.9)

46.0 (24.0)

49.0 (22.3)

0.68

 Impacts

22.9 (18.2)

18.2 (15.9)

24.1 (18.8)

0.17

 Total

33.7 (17.5)

30.7 (16.6)

35.4 (17.5)

0.29

Acute exacerbation in the previous yeara

  ≥ 2 Moderate AE

15 (8.6)

1 (1.5)

6 (10.7)

0.09

  ≥ 1 Severe AE

19 (10.9)

6 (8.8)

7 (12.5)

0.80

  ≥ 2 Moderate or ≥ 1 severe AE

30 (17.1)

7 (10.3)

12 (21.4)

0.23

Self-reported history of asthma

52 (29.7)

17 (25.0)

15 (26.8)

0.74

Spirometry

 FEV1 (mL)

1398.7 (510.2)

1538.1 (531.0)

1533.9 (503.1)

0.08

 FEV1, % predicted

46.5 (15.7)

50.7 (14.8)

49.8 (14.2)

0.10

 FVC (mL)

3234.1 (784.1)

3314.3 (800.4)

3240.2 (775.5)

0.77

 FVC, % predicted

77.7 (17.6)

79.9 (16.1)

75.8 (15.3)

0.41

 FEV1/FVC (%)

43.1 (11.2)

45.9 (9.3)

47.3 (10.2)

0.018

 Post-bronchodilator FEV1 (mL)

1555.6 (531.7)

1690.7 (537.9)

1728.8 (554.1)

0.052

 Post-bronchodilator FEV1, % predicted

51.6 (16.1)

55.9 (14.9)

56.1 (15.4)

0.06

 Post-bronchodilator FEV1 < 50%predicted, n(%)

91 (52.0)

42 (61.8)

34 (60.7)

0.28

 Positive reversibility, n (%)

54 (30.9)

21 (30.9)

19 (33.9)

0.91

Emphysema > 5%b

137 (78.3)

52 (76.5)

43 (76.8)

0.94

Inhaler use

 LAMA

75 (42.9)

22 (32.4)

14 (25.0)

0.036

 ICS/LABA or ICS

71 (40.6)

22 (32.4)

28 (50.0)

0.14

Blood Eosinophils

143.4 (73.4)

339.0 (191.6)

681.0 (595.6)

< 0.001

Interval between two Eosinophil count, months

12.2 (4.5)

12.1 (4.0)

12.9 (6.4)

0.56

  1. The data are presented as number (%) or as mean (SD)
  2. Abbreviations: BMI body mass index, mMRC modified Medical Research Council, SGRQ St George’s Respiratory Questionnaire, AE acute exacerbation, FEV1 forced expiratory volume in 1 second, FVC forced vital capacity, LAMA long acting muscarinic antagonist, ICS inhaled corticosteroids, LABA long acting beta2-agonist, SD standard deviation
  3. aModerate AE was defined as a clinic visit and severe AE was defined as a hospitalization or an emergency room visit owing to one or more of the following: worsening of dyspnea, increased sputum volume and purulent sputum
  4. bEmphysema was defined as a percentage of lung attenuation less than 950 Hounsfield units. Percent emphysema was determined for total lung